Literature DB >> 22228207

Intravitreal kinetics of hesperidin, hesperetin, and hesperidin G: effect of dose and physicochemical properties.

Ramesh Srirangam1, Ketan Hippalgaonkar, Soumyajit Majumdar.   

Abstract

Hesperidin, a flavanone glycoside, and its aglycone hesperetin are potential candidates for the treatment of diabetic retinopathy and macular edema. The objective of this study was to delineate vitreal pharmacokinetics of hesperidin and hesperetin and the hydrophilic derivative glucosyl hesperidin (hesperidin G) following intravitreal administration in anaesthetized rabbits. Concentration changes in vitreous humor were monitored using microdialysis sampling procedure. All three molecules were administered intravitreally at three dose levels (50 µL injection volume containing 1.5, 4.5, and 15 µg of the drug, resulting in a final vitreal concentration of 1, 3, and 10 µg/mL). Vitreal microdialysis samples were collected every 20 min over a period of 10 h. All three molecules exhibited linear pharmacokinetics within the dose range tested because area under the curve and maximum concentration (C(max) ) increased linearly with increasing dose and a significant difference in the elimination parameters such as clearance or half-life was not observed. The vitreal elimination half-life of these three compounds was observed to correlate with the molecular weight and lipophilicity of the molecules. The findings from this study provide practical information that will be useful in the future design of ocular drug delivery strategies for bioflavonoids.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228207      PMCID: PMC4157643          DOI: 10.1002/jps.23047

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  36 in total

Review 1.  Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics.

Authors:  Augustinus Laude; Lay Ean Tan; Clive G Wilson; Gerassimos Lascaratos; Mohammed Elashry; Tariq Aslam; Niall Patton; Baljean Dhillon
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Hesperidin upregulates heme oxygenase-1 to attenuate hydrogen peroxide-induced cell damage in hepatic L02 cells.

Authors:  Ming-Cang Chen; Yi-Yi Ye; Guang Ji; Jian-Wen Liu
Journal:  J Agric Food Chem       Date:  2010-03-24       Impact factor: 5.279

3.  Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells.

Authors:  Eun Jeong Choi; Gi Dae Kim; Kew-Mahn Chee; Gun-Hee Kim
Journal:  Nutrition       Date:  2006-07-03       Impact factor: 4.008

Review 4.  Potential of the bioflavonoids in the prevention/treatment of ocular disorders.

Authors:  Soumyajit Majumdar; Ramesh Srirangam
Journal:  J Pharm Pharmacol       Date:  2010-08       Impact factor: 3.765

5.  Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid.

Authors:  Soumyajit Majumdar; Ramesh Srirangam
Journal:  Pharm Res       Date:  2008-09-23       Impact factor: 4.200

6.  Short-term effects of glucosyl hesperidin and hesperetin on blood pressure and vascular endothelial function in spontaneously hypertensive rats.

Authors:  Masaki Yamamoto; Atsushi Suzuki; Tadashi Hase
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  2008-02       Impact factor: 2.000

7.  Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples.

Authors:  Walter Brand; Marelle G Boersma; Hanneke Bik; Elisabeth F Hoek-van den Hil; Jacques Vervoort; Denis Barron; Walter Meinl; Hansruedi Glatt; Gary Williamson; Peter J van Bladeren; Ivonne M C M Rietjens
Journal:  Drug Metab Dispos       Date:  2010-01-07       Impact factor: 3.922

8.  Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells.

Authors:  In-Young Choi; Su-Jin Kim; Hyun-Ja Jeong; Seong-Heak Park; Yong-Sun Song; Ji-Hyun Lee; Tae-Hee Kang; Jin-Han Park; Gab-Soo Hwang; Eon-Jeong Lee; Seung-Heon Hong; Hyung-Min Kim; Jae-Young Um
Journal:  Mol Cell Biochem       Date:  2007-07-13       Impact factor: 3.396

9.  Antioxidant properties of hesperidin in nicotine-induced lung toxicity.

Authors:  Annida Balakrishnan; Venugopal P Menon
Journal:  Fundam Clin Pharmacol       Date:  2007-10       Impact factor: 2.748

10.  Glucosyl hesperidin prevents endothelial dysfunction and oxidative stress in spontaneously hypertensive rats.

Authors:  Masaki Yamamoto; Atsushi Suzuki; Hiroko Jokura; Naoki Yamamoto; Tadashi Hase
Journal:  Nutrition       Date:  2008-03-10       Impact factor: 4.008

View more
  6 in total

1.  Evaluation of topical hesperetin matrix film for back-of-the-eye delivery.

Authors:  Goutham R Adelli; Tushar Hingorani; Nagendra Punyamurthula; Sai Prachetan Balguri; Soumyajit Majumdar
Journal:  Eur J Pharm Biopharm       Date:  2015-02-26       Impact factor: 5.571

2.  Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.

Authors:  Xiaoxi Liu; Yuhuan Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-23       Impact factor: 2.745

Review 3.  Natural product inhibitors of ocular angiogenesis.

Authors:  Rania S Sulaiman; Halesha D Basavarajappa; Timothy W Corson
Journal:  Exp Eye Res       Date:  2014-10-07       Impact factor: 3.467

4.  Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin.

Authors:  Ramesh Srirangam; Ketan Hippalgaonkar; Bharathi Avula; Ikhlas A Khan; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2012-07-13       Impact factor: 2.671

5.  A Comparative Study of Hesperetin, Hesperidin and Hesperidin Glucoside: Antioxidant, Anti-Inflammatory, and Antibacterial Activities In Vitro.

Authors:  Sung-Sook Choi; Sun-Hyung Lee; Kyung-Ae Lee
Journal:  Antioxidants (Basel)       Date:  2022-08-20

6.  A Pharmacokinetic Study of Mix-160 by LC-MS/MS: Oral Bioavailability of a Dosage Form of Citroflavonoids Mixture.

Authors:  Jesús Alfredo Araujo-León; Rolffy Ortiz-Andrade; Efrén Hernández-Baltazar; Emanuel Hernández-Núñez; Julio César Rivera-Leyva; Víctor Yáñez-Pérez; Priscila Vazquez-Garcia; Carla Georgina Cicero-Sarmiento; Juan Carlos Sánchez-Salgado; Maira Rubí Segura-Campos
Journal:  Molecules       Date:  2022-01-08       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.